– USA, MD – Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today announced that Steven Edelman, MD, clinical professor of medicine at the University of California San Diego-Veterans Affairs Healthcare System, has been appointed to its Board of Directors, effective September 2, 2016.
“Dr. Edelman has been a leader and an innovator in the diabetes field for decades and we are thrilled to now have his perspective and contribution to our board of directors,” said Tim Goodnow, President and Chief Executive Officer of Senseonics. “His expertise in clinical research, application and education, as well as his passion for patient advocacy will be invaluable as we build Senseonics into a leader within the diabetes management market.”
Dr. Edelman is a clinical professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego and the Veterans Affairs Healthcare System of San Diego and the director of the Diabetes Care Clinic VA Medical Center. His research concentrates on developing, testing, and evaluating new technologies and pharmaceutical agents for the treatment of type 1 and type 2 diabetes, with a focus that includes glucose sensing technologies, clinical utilization of continuous glucose monitoring and effective use of anti-diabetic agents.
In 2011, Dr. Edelman received the Distinction in Endocrinology award by the American Association of Clinical Endocrinologists, and in 2009, he was awarded the Diabetes Educator of the year by the American Diabetes Association. Dr. Edelman was also recently named among the top 1% of endocrinologists in the United States by US News and World Report. In addition, Dr. Edelman has authored more than 200 articles and five books. Dr. Edelman was the valedictorian of his medical class at the University of California at Davis, and completed his Endocrinology fellowship at the Joslin and Lahey Clinics in Boston as well as a research fellowship at the University of California at San Diego. As the founder and director of Taking Control of Your Diabetes, a not-for-profit organization with the goal of educating, motivating and engaging people with diabetes and their caregivers, Dr. Edelman has improved the lives of hundreds of thousands of people living with diabetes.
“I look forward to working with the Senseonics team as we share the same commitment to improve the lives of people with diabetes,” said Dr. Edelman. “An implantable CGM system that provides the user with accurate and reliable readings for up to 6 months is an incredible advance in the effort to improve the lives of millions of people living with diabetes. I think the Company has only scratched the surface of what’s possible and I’m excited to help guide the team on behalf of the diabetes community.”
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation CGM system, Eversense, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
